DNTH
Dianthus Therapeutics, Inc.
Related News
SEC Filings
Earnings Trend
Screening
Compare
Economic Calendar
We use cookies in accordance with European GDPR standards to improve site usability, analytics, and deliver personalized advertising.Learn moreCookie Settings
Dianthus Therapeutics is building a neuromuscular franchise around claseprubart, differentiated by clinical profile and financial independence. DNTH holds $1.2B in cash and investments, supporting mu
